Glitazone Pharmacokinetics
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 1: | Line 1: | ||
| - | {| class="wikitable" border="1" width=" | + | {| class="wikitable" border="1" width="100%" style="text-align:center" |
|- | |- | ||
! colspan="6" align="center"| Glitazone [[Pharmacokinetics]] Comparison at Equivalent Dosages | ! colspan="6" align="center"| Glitazone [[Pharmacokinetics]] Comparison at Equivalent Dosages | ||
| Line 45: | Line 45: | ||
! Hepatic <br/>(CYP2C8) | ! Hepatic <br/>(CYP2C8) | ||
|} | |} | ||
| - | For References, See: [[Treatments:Glitazone Pharmacokinetics References|References]] | + | For Pharmacokinetic Data References, See: [[Treatments:Glitazone Pharmacokinetics References|References]] |
Current revision
| Glitazone Pharmacokinetics Comparison at Equivalent Dosages | |||||
|---|---|---|---|---|---|
| Parameter | Pioglitazone (Actos) | Rosiglitazone (Avandia) | |||
| Tmax (hr) | 1.8 | 1 | |||
| Cmax (ng/ml) | 617 | 361 | |||
| Bioavailability (%) | 83 | 99 | |||
| Protein Binding (%) | 99 | 99 | |||
| T1/2 (hr) | 3-8 | 3-4 | |||
| AUC (ng/ml/hr) | 6244 | 2024 | |||
| IC50 (nM) | 360 | 10 | |||
| Equivalent Dosage (mg) | 30 | 4 | |||
| Metabolism | Hepatic (CYP2C8) | Hepatic (CYP2C8) | |||
For Pharmacokinetic Data References, See: References
